Результаты поиска

Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

BACKGROUND: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival. METHODS: We explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the Ger…

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM). PATIENTS AND METHODS: Clinical and laboratory data from 4,445 patients with NDMM enrolled onto 11 international trials were pooled together. The K-adaptive partitioning algori…

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.

Patients with multiple myeloma commonly develop focal osteolytic bone disease, as well as generalised osteoporosis. The mechanisms underlying the development of osteoporosis in patients with myeloma are poorly understood. Although disruption of the RANKL/OPG pathway has been shown to underlie formation of focal osteolytic lesions, its role in the development of osteoporosis in myeloma remains unclear. Increased soluble RANKL in serum from patients with myeloma raises the possibility that this molecule plays a key role. The aim of the present study was to establish whether sRANKL produced by my…

Availability of pharmacological treatments for multiple myeloma in Spain.

OBJECTIVES: The treatment of multiple myeloma (MM) has changed substantially in the last two decades due to many therapeutic innovations. This study aims to analyse the authorization trends of drug regimens for the treatment of MM in Spain and evaluate their availability within the Spanish National Health System (NHS). METHODS: Drug regimens authorized in the European Union (EU) and/or in Spain for MM treatment between April 2004 and November 2024 were identified through regulatory agencies' websites. Authorization trends were analysed by number of components, line of treatment and approval f…

Epigenetic reprogramming in multiple myeloma-Challenges and opportunities.

In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly. Multiple myeloma is characterised by high levels of inter- and intra-patient heterogeneity at both the genetic and epigenetic levels. Understanding the many layers of genetic and non-genetic evolution and their interplay is crucial to improve patient outcomes. In this shor…

Next Generation Sequencing in the Diagnosis of Multiple Myeloma.

Multiple myeloma (MM) is a biologically and clinically heterogeneous plasma cell malignancy characterized by clonal expansion in the bone marrow and a highly variable clinical course. Despite major therapeutic advances, MM remains incurable, largely due to the associated genomic complexity, clonal evolution, and the emergence of treatment resistance. In this context, next-generation sequencing (NGS) has emerged as a transformative tool for improving disease characterization, risk stratification, and clinical management. This review summarizes current evidence on the application of NGS technolo…

[Expression Level and Function of UBE2QL1 in Multiple Myeloma].

OBJECTIVE: To investigate the expression level of UBE2QL1 in multiple myeloma (MM) and its correlation with disease progression and prognosis, as well as to elucidate the biological role of UBE2QL1 in MM through in vitro cell experiments. METHODS: Bioinformatics analysis was used to explore the expression level of UBE2QL1 in MM and its impact on prognosis. Concurrently, a polyclonal antibody against UBE2QL1 was synthesized, and its specificity was confirmed through mass spectrometry. The expression level of UBE2QL1 in MM cell lines and primary bone marrow samples was validated using qRT-PCR a…

Multiple Myeloma: Insights Into a Challenging Diagnostic Journey.

IntroductionMultiple myeloma (MM), an incurable plasma cell malignancy, is one of the most challenging cancers to diagnose. Diagnostic delays are associated with increased complications and worse outcomes. Existing knowledge of MM diagnostic pathways largely relies on secondary data that fails to capture important details of MM patients' diagnostic journeys. The aim of this study was to explore patients' journeys from initial symptom onset to MM diagnosis and to identify barriers and facilitators to timely diagnostic resolution.MethodsWe conducted a qualitative descriptive study using semi-str…

Assessment tools for peripheral neuropathy in multiple myeloma.

Advances in treating multiple myeloma (MM) have improved survival, shifting the management focus toward quality of life. Peripheral neuropathy (PN) is a common treatment-related toxicity that significantly impairs quality of life. However, standardized assessment methods for PN in patients with MM are currently lacking. A comprehensive search of multiple databases (PubMed, Embase, Cochrane Library, and KoreaMed) was conducted to identify relevant records. Eligible studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Twenty-…

Клинические и лабораторные прогнозы смертности в множестве миеломы

Abstract Force Multieloma (MM) — плазменная порча клеток, характеризующаяся инфильтрацией костного мозга и дисфункцией органов. Несмотря на прогресс в лечении, болезнь имеет разнородные клинические результаты, что требует надежных прогнозов. Прогнозируемое значение процентной доли плазменных клеток костного мозга (ПХ) и фиброза ретикулина для прогнозирования смертности остается неясным и противоречивым в литературе. Мы провели ретроспективный анализ 97 пациентов, у которых диагностировали миелому. Процент костного мозга (PC) и ретикулиновый фиброз был оценен наряду с всеобъемлющими клиническим

Совпадение в аннотации оригинала
Abstract Background Multiple myeloma (MM) is a plasma cell malignancy characterized by bone marrow infiltration and organ dysfunction. Despite advances in treatment, the disease exhibits heterogeneous clinical outcomes, necessitating reliable prognostic markers. The prognostic significance of bone marrow plasma cell (PC) percentage and reticulin fibrosis in …

Orbital Plasmacytoma as Initial Presentation of Multiple Myeloma.

Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow. It represents approximately 10% of hematologic malignancies and is the most common primary bone malignancy. This disease usually occurs between the ages of 40 and 70, although it is more frequently seen in patients over 65 years of age. On the other hand, extramedullary plasmacytoma-related diseases have a global annual incidence of three per 100,000 people. Orbital involvement in MM is considered rare. Orbital plasmacytomas represent less than 1% of all orbital lesions, …

Несекретарша Множественная Миэлома: Вызов диагностике.

Несекретарская миелома (NSMM) — редкий вариант множественной миеломы с коэффициентом заболеваемости от 1,0% до 5,0% во всех случаях MM. Для него характерна симптоматическая миелома при отсутствии обнаруживаемого моноклонального иммуноглобулина на сыворотке или электрофорезе мочи. Она часто создает диагностическую дилемму в связи с тем, что ей необходимы более очевидные черты. Мы сообщали о такой несекретной плазменной миэломе, которая проявляла неконкретную боль в спине и литическое повреждение поясничного позвоночника MRI. Подтверждение точного диагноза на раннем этапе было сопряжено с трудно…

Факторы риска и их влияние на прогноз в множестве миеломы.

Несмотря на улучшение клинических результатов по миеломе (ММ), некоторые пациенты по-прежнему не выживают, а выявление пациентов с повышенным риском (РМ) на ранней стадии остается серьезной проблемой. В этом исследовании мы собрали недавно опубликованные рекомендации Международного общества миеломы (МСМ)/Международной рабочей группы по миеломе (МРГМ) и четыре дополнительных фактора риска различного характера (мобилизационная активность АПОБЕК, хромотрипс, сигнатура выражения генов EMC92, индекс распространения (PR)) и изучили их предсказующую полезность для данных КоМпасса. Все факторы были в

Совпадение в аннотации оригинала
Despite improvements in clinical outcomes for multiple myeloma (MM), some patients still experience short survival, and identifying high-risk (HR) MM patients early remains a substantial challenge. In this study, we collected recently published International Myeloma Society (IMS) / International Myeloma Working Group (IMWG) recommendation and four additional…

Хроническая нейтрофическая лейкемия у пациента с множественной миеломой.

Высокодозированная химиотерапия, применяемая для аутологической трансплантации стволовых клеток (ASCT), часто связана с распространением клеток с неопластическими способностями. В результате может быть расширена одна конкретная линия клеток, т.е. клональная гематомоизис (CH). Частота CH в множестве миеломы (ММ) была зарегистрирована как ~21,6%. Хотя нейтрофия в MM может быть лейкемоидной реакцией, нельзя забывать о таких гематоологических новообразованиях, как хроническая нейтрофильная лейкемия (CNL), которая характеризуется мутации CSF3R и отсутствием цитопении и/или значительного морфологиче

Совпадение в аннотации оригинала
High-dose chemotherapy used for autologous stem cell transplantation (ASCT) is often associated with the proliferation of cells with neoplastic capabilities. As a result, expansion of one particular cell line, i.e., clonal hematopoiesis (CH), can occur. The frequency of CH in multiple myeloma (MM) has been reported as ~21.6%. Although neutrophilia in MM coul…

Home-Based Daratumumab in Patients With Multiple Myeloma.

OBJECTIVE: Multiple myeloma is an incurable cancer with lifelong treatment needs. This, together with a global nursing shortage, calls for new approaches for future treatment. In this study, we therefore investigated the feasibility of home-based subcutaneous daratumumab administered by primary care nurses outside the hospital. METHODS: Applying a mixed-methods prospective design, we included 30 patients; 18 had completed ≥ 6 cycles of daratumumab treatment, and 12 were newly started. New patients were followed for six 28-day cycles, with every second treatment administered outside the hospit…